RISK ASSESSMENT (EMCDDA)

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4- yl]oxolane-2-carboxamide (THF-F) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of N-(1?phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP)

Report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 4,4′-DMAR in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of 4-methylamphetamine in the framework of the Council Decision on new psychoactive substances

Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances

Risk assessment of new psychoactive substances — operating guidelines

Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances

Early-warning system on new psychoactive substances — operating guidelines

Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs

Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs

Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs

Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs

Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs

Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs

Guidelines for the risk assessment of new synthetic drugs

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs


София 1303, ул. Пиротска 117

тел.: 02/ 832 61 36, 832 61 37, 831 30 79
факс: 02/ 831 30 79
www.nfp-drugs.bg
e-mail: office@nfp-drugs.bg

София 1303, ул. Пиротска 117

Директор / Секретар: 02/ 831 90 15
централа: 02/ 832 61 36
факс: 02/ 832 10 47
www.ncn-bg.org
e-mail: office@ncn-bg.org ; ncn@infotel.bg
Информацията в този сайт не може да се възпроизвежда по какъвто и да е начин без писмено съгласие.